Co-amoxiclav Renal Dose Adjustments
For patients with renal impairment, co-amoxiclav requires dose adjustment based on creatinine clearance, with the standard 875mg/125mg tablet formulation requiring interval extension rather than dose reduction to maintain therapeutic efficacy while preventing accumulation.
Dosing Algorithm by Renal Function
Normal Renal Function (CrCl >30 mL/min)
- Standard dosing: 875mg/125mg every 12 hours OR 500mg/125mg every 8 hours
- No adjustment needed 1
Moderate Renal Impairment (CrCl 10-30 mL/min)
- Recommended: 500mg/125mg every 12-24 hours
- Extend dosing interval rather than reducing individual doses 2
- The differential clearance between amoxicillin and clavulanate becomes clinically significant in this range
Severe Renal Impairment (CrCl <10 mL/min)
- Recommended: 500mg/125mg every 24 hours
- Monitor for accumulation, particularly of amoxicillin component 2
Hemodialysis Patients
- Recommended: 500mg/125mg every 24 hours
- Critical timing: Administer dose AFTER dialysis session 2, 3
- Both amoxicillin and clavulanate are removed by hemodialysis, with clavulanate having higher extraction ratio (0.74 vs 0.44) 3
- Supplemental dosing post-dialysis prevents subtherapeutic levels
Key Pharmacokinetic Considerations
The amoxicillin-to-clavulanate ratio increases dramatically with declining renal function 2. In patients with normal renal function (GFR ~75 mL/min), the AUC ratio is approximately 4.9:1. This ratio increases to 14.7:1 in hemodialysis patients, indicating disproportionate amoxicillin accumulation. This differential accumulation explains why interval extension is preferred over dose reduction—it maintains adequate clavulanate levels while preventing excessive amoxicillin accumulation.
Both components show:
- Volume of distribution independent of renal function
- Systemic bioavailability unchanged by renal impairment
- Total body clearance decreases proportionally with declining GFR 2
Common Pitfalls to Avoid
Do NOT substitute different formulations in renal impairment. The 600mg/42.9mg per 5mL pediatric suspension contains different clavulanate ratios than standard formulations and should never be used interchangeably 1. The 200mg/28.5mg and 400mg/57mg suspensions are NOT equivalent to the 600mg/42.9mg formulation.
Do NOT reduce individual doses below 500mg/125mg in adults. Concentration-dependent killing requires adequate peak levels. Instead, extend the dosing interval to prevent accumulation while maintaining efficacy 2.
Monitor hepatic function concurrently in renally impaired patients, as hepatic impairment requires additional caution with co-amoxiclav dosing 1.